emerg
reemerg
virus
caus
human
diseas
becom
greater
concern
public
health
good
exampl
sar
coronaviru
sarscov
viru
first
appear
human
popul
late
eventu
infect
peopl
fatal
rate
today
avian
influenza
viru
pose
signific
threat
effect
transmiss
develop
potenti
risk
spanish
flulik
pandem
juckett
tellier
thoma
noppenberg
emerg
virus
biothreat
agent
rais
world
concern
use
biowarfarebioterror
demonstr
vulner
societi
biolog
threat
tradit
protect
pathogen
achiev
either
activ
passiv
immun
activ
immun
vaccin
administ
elicit
protect
immun
respons
gener
desir
therapeut
goal
unfortun
vaccin
develop
slow
expens
case
biothreat
agent
vaccin
often
fail
market
attract
commerci
research
develop
fund
passiv
immun
specif
antibodi
administ
viabl
altern
provid
immedi
protect
immun
casadeval
sudden
unexpect
terrorist
attack
immediaci
protect
provid
passiv
protect
antibodi
especi
import
halflif
human
serum
immunoglobulin
day
passiv
immun
could
provid
effect
countermeasur
biolog
weapon
casadeval
challeng
lie
abl
rapidli
respond
biolog
insult
gener
specif
antibodi
product
effect
antibodi
subject
extens
research
signific
success
ie
recombin
antibodi
approv
therapeut
fda
mani
organ
involv
work
either
focu
discoveri
novel
antibodi
subsequ
outsourc
necessari
optim
effort
vice
versa
contrast
util
technolog
comprehens
encompass
discoveri
optim
compon
produc
therapeut
antibodi
addit
elimin
potenti
coordin
issu
organ
central
effort
reduc
timelin
use
sarscov
model
system
discov
human
optim
function
perform
novel
neutral
antibodi
inhibit
sar
infect
permiss
cell
viral
replic
vivo
discoveri
evolut
strategi
potenti
use
reduc
current
suscept
biolog
threat
librari
plasmid
pbadzf
construct
sever
step
use
pbadgiii
invitrogen
carlsbad
ca
usa
start
plasmid
cassett
contain
polynucleotid
encod
zinc
finger
protein
flag
tag
tag
insert
ndeipmei
site
next
zinc
finger
bind
domain
sequenc
insert
plasmid
termin
sitedirect
mutagenesi
stratagen
la
jolla
ca
usa
final
product
vector
pbadzf
use
clone
express
antibodi
light
heavi
chain
describ
ten
balbc
mice
immun
sucros
gradient
purifi
sar
viru
center
diseas
control
prevent
cdc
strain
origin
provid
dr
thoma
g
ksiazek
special
pathogen
branch
cdc
atlanta
ga
usa
mous
initi
dose
plaqu
form
unit
pfu
live
viru
intraperiton
ip
rout
day
follow
dose
viru
day
antibodi
titer
sarscov
elisa
rang
spleen
three
mice
remov
process
steril
mesh
screen
wash
dulbecco
minim
essenti
medium
dmem
penicillin
iuml
streptomycin
pellet
centrifug
min
rpm
cell
pellet
resuspend
dmem
contain
antibiot
dmso
fetal
bovin
serum
store
liquid
nitrogen
rna
extract
use
trizol
ls
invitrogen
carlsbad
ca
usa
frozen
splenocyt
cdna
librari
construct
use
bd
kit
bd
bioscienc
san
jose
ca
usa
isol
cdna
light
chain
antibodi
domain
amplifi
use
vl
forward
primer
kappa
revers
primer
oligonucleotid
sequenc
describ
essono
et
al
repres
light
chain
cdna
encod
heavi
chain
antibodi
domain
amplifi
use
vh
forward
primer
six
revers
primer
complement
repres
heavi
chain
subset
possibl
forward
primer
use
construct
librari
simpli
limit
number
primer
requir
librari
construct
light
heavychain
pcr
product
fuse
overlap
pcr
antibodi
light
heavi
chain
clone
ndei
paci
restrict
site
form
pbadfabzf
cassett
contain
nucleotid
sequenc
encod
light
chain
antibodi
domain
nontransl
linker
heavi
chain
antibodi
domain
fuse
infram
nterminu
zinc
finger
protein
light
heavi
chainzinc
finger
protein
express
separ
polypeptid
chain
pbadfabzf
transform
high
effici
cell
plasmid
isol
subsequ
transform
compet
cell
novagen
madison
wi
usa
librari
stock
transform
express
host
cell
store
glycerol
ml
aliquot
luriabertani
lb
media
contain
carbenicillin
lbcarb
inocul
dna
display
librari
glycerol
stock
contain
cell
pbadfabzf
cell
grown
shake
h
induc
h
ad
arabinos
mm
induc
cell
centrifug
min
rpm
supernat
remov
cell
pellet
resuspend
sonic
buffer
mm
dtt
tween
mgml
salmon
sperm
dna
mgml
bovin
serum
albumin
bsa
milk
powder
mm
naglutam
mm
hepe
ph
centrifug
resuspend
sonic
buffer
cell
sonic
centrifug
rpm
min
supernat
remov
kept
ice
magnet
dynal
bead
epoxi
label
use
mgml
antigen
invitrogen
carlsbad
ca
usa
bead
wash
fresh
sonic
buffer
ad
cell
lysat
describ
mix
rotat
least
min
room
temperatur
supernat
remov
bead
wash
ml
sonic
buffer
follow
ml
wash
buffer
sonic
buffer
without
salmon
sperm
dna
bead
centrifug
remain
buffer
remov
next
bead
mix
min
wash
buffer
plu
nacl
dissoci
zinc
complex
supernat
contain
elut
plasmid
remov
elut
plasmid
dna
purifi
use
roch
high
pure
pcr
product
purif
kit
roch
diagnost
manheim
germani
transform
high
transform
effici
escherichia
coli
e
coli
cell
heat
shock
min
transform
cell
grown
lbcarbenicillin
agar
plate
harvest
plasmid
dna
recov
use
qiaprep
spin
miniprep
kit
qiagen
valencia
ca
usa
case
plasmid
dna
taken
anoth
cycl
screen
addit
enrich
confirm
clone
isol
discoveri
screen
recov
plasmid
retransform
rosettagami
strain
plate
agar
approxim
singl
coloni
select
place
plate
contain
ml
lbcarb
cell
grown
h
dilut
ml
lbcarb
dilut
cell
grown
induc
middl
log
phase
arabinos
mm
h
cell
plate
pellet
centrifug
min
rpm
resuspend
sonic
buffer
transfer
skirt
pcr
plate
fisher
scientif
pittsburgh
pa
usa
cell
sonic
min
icebath
chill
micropl
horn
misonix
farmingdal
ny
usa
sonic
plate
centrifug
rpm
min
lysat
ad
directli
onto
antigenco
elisa
plate
antigenco
nunc
maxisorp
plate
ie
spike
protein
infect
cell
lysat
whole
sar
viru
prepar
incub
antigenwel
overnight
wash
pb
tween
pbst
case
half
plate
coat
bsa
determin
nonspecif
bind
plate
block
overnight
block
buffer
pbst
dri
milk
powder
bsa
plate
wash
four
time
pbst
induc
supernat
ad
h
room
temperatur
follow
wash
pbst
rat
antimous
kappa
light
chain
antibodi
conjug
peroxidas
invitrogen
carlsbad
ca
usa
ad
incub
h
wash
pbst
subsequ
tmb
kpl
gaithersburg
md
usa
incub
min
room
temperatur
phosphor
acid
ad
stop
reaction
absorb
od
nm
measur
use
spectromax
plu
spectrophotomet
molecular
devic
sunnyval
ca
usa
follow
sequenc
variabl
domain
heavi
light
chain
clone
frame
respect
human
constant
domain
two
separ
express
vector
invitrogen
carlsbad
ca
usa
antibodi
express
cotransfect
vector
cell
use
invitrogen
carlsbad
ca
usa
cell
grown
ml
scale
l
flask
freestyl
media
shake
rpm
seven
day
supernat
harvest
follow
min
spin
g
antibodi
purifi
supernat
use
protein
g
hp
column
amersham
piscataway
nj
usa
fast
protein
liquid
chromatographi
fplc
purifi
igg
quantifi
bca
protein
assay
analyz
sd
gel
assay
presenc
endotoxin
use
chromogen
limulu
amebocyt
lysat
test
lonza
rockland
usa
necessari
prepar
pass
polymyxin
b
gel
column
detoxigel
pierc
endotoxin
remov
sarscov
spike
protein
protein
scienc
lexington
ky
usa
label
biotin
use
biotin
protein
label
kit
roch
diagnost
penzberg
germani
test
fab
igg
nm
final
concentr
spike
protein
ad
variou
concentr
fab
igg
pb
spike
solut
incub
room
temperatur
min
incub
overnight
vero
cell
atcc
manassa
va
usa
grown
minim
essenti
medium
contain
penicillin
iuml
streptomycin
mm
lglutamin
mm
pyruv
acid
fetal
bovin
serum
invitrogen
carlsbad
ca
usa
confluent
follow
trypsin
vero
cell
harvest
centrifug
g
min
wash
pb
resuspend
pb
cellsml
vero
cell
suspens
ad
solut
incub
room
temperatur
h
sampl
wash
three
time
centrifug
pb
resuspend
pb
contain
invitrogen
carlsbad
ca
usa
incub
h
room
temperatur
incub
cell
wash
pb
resuspend
pb
analyz
dako
moflo
flow
cytomet
dako
fort
collin
co
usa
antibodi
dilut
earl
minimum
essenti
medium
emem
contain
fetal
bovin
serum
antibiot
penicillin
iuml
streptomycin
polyclon
rabbit
serum
use
posit
control
diluent
neg
control
set
sampl
test
approxim
pfu
sarscov
emem
media
ad
equal
volum
dilut
antibodi
incub
overnight
incub
virusantibodi
mixtur
appli
confluent
monolay
vero
cell
grown
sixwel
tissu
cultur
plate
adsorb
h
incub
plate
overlaid
emem
agaros
medium
contain
fetal
bovin
serum
antibiot
incub
h
incub
plaqu
visual
stain
second
emem
agaros
overlay
contain
fetal
bovin
serum
neutral
red
antibiot
plaqu
count
h
stain
plaqu
reduct
neutral
titer
calcul
rel
neg
control
complementar
determin
region
cdr
mous
antibodi
sequenc
identifi
http
wwwbioinforgukab
dsdna
cdr
fragment
creat
anneal
synthet
oligonucleotid
encod
mous
sequenc
oligo
design
leav
singl
strand
overhang
side
compat
framework
fragment
framework
fragment
design
repres
sequenc
divers
exhibit
first
three
human
framework
region
fr
separ
fragment
librari
construct
base
human
germlin
immunoglobulin
heavi
light
chain
variabl
domain
vh
vl
human
variabl
domain
natur
immunolog
matur
process
fr
sever
fragment
design
repres
divers
seen
among
natur
fr
cdr
best
neutral
antibodi
combin
possibl
combin
fr
fragment
librari
gener
novel
vh
vl
construct
kappa
light
chain
total
number
possibl
combin
reassembl
framework
number
uniqu
sequenc
heavi
chain
number
uniqu
sequenc
dsdna
hook
fragment
attach
streptavidinco
magnet
bead
fulllength
variabl
domain
synthes
ligat
pool
framework
hook
wash
unbound
materi
ligat
cdr
follow
pool
framework
fragment
ad
correct
order
fulllength
reassembl
product
separ
bead
appropri
restrict
enzym
clone
vector
contain
mammalian
secret
signal
either
kappa
light
chain
constant
domain
constant
domain
ligat
product
transform
e
coli
sequenc
eight
light
chain
design
synthes
menlo
park
ca
usa
addit
reassembl
librari
light
chain
repres
one
eight
sequenc
cluster
identifi
bioinformat
analysi
gene
site
satur
mutagenesi
perform
describ
previous
kretz
et
al
use
degener
oligonucleotid
random
codon
cdr
region
possibl
amino
acid
would
encod
mutat
dna
pool
transform
cell
possibl
variant
site
identifi
sequenc
analysi
sequenc
two
plate
clone
found
least
usual
greater
possibl
amino
acid
repres
posit
decid
divers
suffici
screen
approxim
residu
requir
extra
plate
variant
sequenc
order
achiev
least
amino
acid
chang
follow
sequenc
analysi
human
framework
reassembl
librari
appropri
clone
identifi
array
deep
plate
cultur
grown
h
shake
plasmid
dna
isol
use
perfectprep
plasmid
isol
kit
eppendorf
hamburg
germani
use
autom
robot
system
plate
contain
cell
confluent
transfect
plasmid
grown
five
day
supernat
harvest
five
day
two
elisa
perform
plate
use
robot
system
one
elisa
function
elisa
use
spike
protein
antigen
follow
protocol
describ
except
secondari
antibodi
antihuman
kappa
antibodi
conjug
peroxidas
sigma
st
loui
mo
usa
second
elisa
measur
rel
amount
antibodi
express
elisa
similar
function
assay
except
streptavidinco
plate
sigma
st
loui
mo
usa
use
biotinyl
antihuman
igg
sigma
st
loui
mo
usa
captur
express
antibodi
plate
kinet
human
chimera
antibodi
test
use
surfac
plasmon
reson
technolog
biacor
antibodi
captur
onto
sensor
surfac
use
antihuman
igg
antibodi
desir
level
ru
bind
sar
spike
protein
test
nm
highest
concentr
antibodi
respect
dilut
seri
sampl
concentr
seri
test
duplic
surfac
fulli
regener
two
puls
dilut
phosphor
acid
retir
breeder
balbc
mice
split
two
group
one
group
inject
ip
mgkg
best
optim
antibodi
second
group
inject
ip
similar
dose
irrelev
isotypematch
antibodi
immedi
follow
antibodi
inject
mice
challeng
aerosol
exposur
sarscov
use
wholebodi
chamber
within
class
iii
biolog
safeti
cabinet
maintain
neg
pressur
min
aerosol
creat
threejet
collison
nebul
bgi
inc
waltham
usa
control
autom
bioaerosol
exposur
system
hart
aerosol
concentr
viru
determin
constant
sampl
chamber
use
allglass
imping
agi
ace
glass
vineland
nj
usa
hank
balanc
salt
solut
hbss
contain
fetal
calf
serum
antifoam
collect
medium
viru
concentr
start
solut
allglass
imping
agi
determin
plaqu
assay
determin
present
dose
calcul
use
respiratori
minut
volum
vm
estim
deriv
guyton
formula
vm
wb
bodi
weight
present
dose
calcul
multipli
total
volum
vt
experiment
atmospher
inhal
vt
vm
length
exposur
aerosol
concentr
ce
present
dose
ce
vt
inhal
dose
pfu
base
concentr
viru
aerosol
predict
volum
air
mous
inhal
min
day
follow
challeng
mice
sacrif
lung
remov
analysi
lung
homogen
test
presenc
viru
plaqu
assay
vero
cell
lower
limit
detect
pfug
two
librari
construct
spleen
three
mice
immun
sarscov
librari
complex
member
gener
revers
transcript
polymeras
chain
reaction
use
antibodyspecif
primer
smaller
librari
gener
proof
principl
studi
larger
subsequ
made
increas
screen
popul
screen
librari
accomplish
use
novel
high
throughput
dna
display
methodolog
fig
techniqu
involv
intracellular
express
fab
fragment
fusion
protein
zinc
finger
zinc
finger
bind
correspond
dna
bind
domain
plasmid
fusion
protein
bind
dna
encod
genotyp
follow
cell
lysi
complex
pan
antigen
interest
fusion
complex
found
extrem
stabl
biacor
analysi
data
shown
halflif
h
room
temperatur
also
note
test
done
ensur
plasmid
switch
occur
time
ie
complex
dissoci
fusion
protein
bind
wrong
plasmid
multipl
separ
screen
perform
use
dynal
bead
coat
spike
protein
whole
viral
isol
infect
cell
lysat
antigen
screen
result
hundr
potenti
candid
three
differ
antigen
prepar
confirm
priorit
potenti
hit
perform
sandwich
elisa
use
spike
protein
captur
antigen
rel
antibodi
express
level
measur
second
elisa
subsequ
use
determin
specif
activ
ie
function
elisaquantit
elisa
variou
antisar
fab
seventyeight
fab
candid
exhibit
confirm
bind
activ
spike
protein
figur
data
one
elisa
plate
demonstr
recoveri
rate
sarsreact
antibodi
screen
twentyeight
antibodi
bound
spike
protein
greater
activ
background
candid
describ
test
abil
block
bind
spike
protein
vero
cell
known
carri
receptor
respons
mediat
sar
viru
entri
six
candid
inhibit
bind
spike
protein
vero
cell
fig
six
clone
three
fab
uniqu
follow
sequenc
analysi
clone
repres
twice
three
antibodi
came
experi
use
spike
protein
antigen
discoveri
screen
three
fab
along
six
other
convert
chimer
form
contain
human
constant
region
mous
variabl
region
minu
dna
bind
domain
fusion
three
antibodi
retain
abil
block
spike
protein
bind
vero
cell
data
shown
purifi
antibodi
test
plaqu
reduct
neutral
test
prnt
use
live
sar
viru
permiss
vero
cell
line
result
summar
tabl
show
five
antibodi
exhibit
neutral
activ
concentr
rang
three
antibodi
block
spike
bind
vero
cell
ie
also
show
neutral
prnt
two
addit
antibodi
block
spike
bind
neutral
sar
infect
suggest
inhibitori
mechan
direct
blockag
receptor
bind
epitop
one
antibodi
discov
use
viral
isol
antigen
show
neutral
concentr
respect
exhibit
best
neutral
activ
chosen
subsequ
optim
studi
potenti
antibodi
use
human
therapeut
technolog
use
convert
mous
variabl
region
sequenc
antibodi
human
antibodi
sequenc
random
combin
possibl
heavi
light
chain
result
combin
respect
limit
size
screen
divid
two
part
heavi
chain
librari
screen
first
follow
light
chain
librari
first
screen
use
eight
fix
light
chain
compos
three
cdr
mous
variabl
region
togeth
consensu
sequenc
select
pool
four
defin
framework
famili
variabl
region
eight
light
chain
pair
heavi
chain
librari
compos
uniqu
variant
array
duplic
four
plate
clone
per
plate
total
plate
clone
supernat
deriv
transfect
framework
librari
assay
function
activ
ie
reactiv
sar
spike
protein
rel
antibodi
express
level
ie
product
suffici
antibodi
initi
screen
uniqu
hit
chosen
specif
activ
greater
normal
chimera
ie
follow
confirm
hit
assay
duplic
use
two
elisa
assay
top
perform
chosen
base
normal
specif
activ
ie
degre
bind
activ
purifi
spike
protein
normal
igg
concentr
normal
specif
activ
origin
chimer
antibodi
best
perform
specif
activ
rang
fig
second
screen
consist
heavi
chain
candid
pair
light
chain
librari
compos
variant
array
duplic
four
plate
total
plate
clone
initi
screen
hit
chosen
specif
activ
compar
origin
antibodi
hit
deriv
primari
screen
assay
duplic
use
elisa
assay
top
perform
secondari
screen
exhibit
specif
activ
rang
around
high
low
greater
chimera
fig
high
low
valu
chosen
due
high
level
express
valu
low
express
rel
high
function
activ
valu
five
heavi
chain
appear
top
light
chain
candid
one
heavi
chain
repres
five
clone
top
antibodi
purifi
analyz
prnt
use
live
sarscov
permiss
vero
cell
line
result
summar
fig
show
one
human
clone
achiev
neutral
sar
viru
lower
concentr
compar
chimera
wt
second
human
clone
equal
wt
clone
shown
fig
neutral
capabl
less
wildtyp
wt
ie
thu
screen
clone
duplic
found
two
human
antibodi
either
maintain
function
activ
show
enhanc
activ
fact
clone
exhibit
lower
neutral
activ
wt
although
show
enhanc
bind
spike
protein
surpris
one
expect
perfect
correl
exist
spike
protein
elisa
sar
viral
neutral
assay
neutral
effici
depend
mani
differ
antibodybind
characterist
eg
epitop
recognit
fine
specif
reaction
rate
kinet
evid
affin
antibodi
correl
well
neutral
abil
burton
hudson
souraiu
nelson
et
al
mind
cdr
region
subject
affin
matur
strategi
call
method
produc
everi
possibl
amino
acid
site
individu
within
protein
region
interest
amino
acid
three
cdr
region
light
heavi
chain
respect
screen
perform
simultan
screen
amino
acid
individu
mutat
possibl
codon
backbon
chimera
clone
sequenc
identifi
appropri
amino
acid
chang
array
duplic
plate
two
amino
acid
posit
per
plate
amino
acid
per
posit
total
clone
thu
total
number
plate
screen
amino
acid
found
cdr
region
plate
clone
antibodi
variant
screen
function
quantit
elisa
framework
reassembl
screen
initi
screen
clone
chosen
exhibit
specif
activ
normal
chimera
clone
deriv
primari
screen
assay
duplic
elisa
assay
top
perform
chosen
antibodi
normal
chimera
show
specif
activ
rang
fig
purifi
antibodi
subsequ
analyz
prnt
two
variant
achiev
neutral
lower
concentr
wt
chimer
antibodi
variant
neutral
activ
lowest
titer
use
ie
clone
shown
neutral
capabl
higher
concentr
wt
chimera
rang
experi
suggest
often
signific
addit
synergist
effect
function
activ
combin
benefici
singl
point
mutat
gray
et
al
palack
et
al
addit
want
best
antibodi
human
framework
thu
new
librari
construct
place
combin
posit
neutral
singl
point
mutat
backbon
framework
reassembl
clone
two
framework
clone
use
backbon
librari
clone
uniqu
light
chain
pair
heavi
chain
framework
clone
four
differ
point
mutat
chosen
light
chain
singl
mutat
heavi
chain
tabl
ii
total
librari
size
possibl
combin
screen
two
elisa
describ
top
perform
better
bind
activ
compar
wt
chimera
fig
prnt
variant
achiev
neutral
sar
viru
concentr
equal
lower
wt
chimera
best
antibodi
ie
achiev
neutral
lower
concentr
wt
fig
variant
equal
abil
wt
antibodi
shown
determin
whether
enhanc
neutral
effici
correl
increas
affin
kinet
wt
antibodi
measur
improv
affin
observ
compar
wt
chimera
kd
versu
nm
respect
tabl
iii
variant
contain
two
mutat
top
two
individu
clone
place
light
chain
framework
exhibit
best
activ
tabl
ii
addit
synergist
effect
observ
somewhat
less
effect
neutral
alon
could
due
small
librari
size
andor
simultan
chang
two
possibl
human
framework
antibodi
studi
vivo
determin
abil
inhibit
viral
replic
lung
age
mice
initi
studi
demonstr
exposur
age
balbc
mice
aerosol
contain
sarscov
result
viral
replic
lung
patholog
similar
result
report
intranas
exposur
robert
et
al
lower
dose
data
shown
mice
inject
irrelev
control
antibodi
immedi
challeng
aerosol
sar
three
day
later
mice
necropsi
lung
taken
viral
isol
except
two
mice
die
unexpectedli
immedi
follow
inject
sarscov
challeng
dose
mgkg
replic
sarscov
lung
reduc
sever
anim
show
evid
sar
viru
lung
tabl
iv
work
introduc
novel
dna
display
method
rapid
screen
function
antibodi
display
technolog
method
bypass
labori
task
hybridoma
product
perhap
importantli
allow
access
total
divers
antibodi
found
within
mice
fact
heavi
chain
chanc
interact
light
chain
method
provid
even
greater
divers
found
mice
screen
immun
mous
librari
antibodi
spike
protein
three
antibodi
isol
inhibit
infect
sarscov
vero
cell
librari
recov
three
immun
mice
pair
three
addit
mice
immun
viru
schedul
three
mice
significantli
higher
serum
antibodi
titer
sarscov
use
gener
antibodi
follow
tradit
hybridoma
approach
although
analysi
hybridoma
conduct
sole
sar
viru
rather
spike
protein
alon
interest
note
neutral
antibodi
found
use
hybridoma
approach
data
shown
multipl
neutral
antibodi
found
use
dna
display
mani
protein
display
system
describ
literatur
gener
fall
three
categori
viral
display
cell
surfac
display
dnarna
display
li
phagebas
system
among
commonli
use
method
typic
base
fusion
protein
interest
coat
protein
express
phage
surfac
despit
signific
success
limit
approach
exampl
fusion
phage
protein
aspect
phage
display
may
interfer
bind
properti
protein
interest
well
multisubunit
protein
difficult
screen
phage
display
final
phage
display
protein
transport
cell
surfac
vitro
environ
might
suitabl
interact
ribosom
display
limit
protein
made
entir
vitro
thu
might
right
chaperon
necessari
cofactor
appropri
redox
state
fold
properli
dna
display
method
describ
combin
vivo
product
protein
vitro
screen
desir
protein
characterist
vitro
screen
allow
highthroughput
analysi
complex
librari
great
divers
vivo
product
made
function
fab
specif
e
coli
redox
strain
allow
proper
intracellular
environ
fab
product
suffici
concentr
perform
screen
fab
produc
fusion
zinc
finger
fab
heavi
chain
opposit
construct
light
chain
fuse
zinc
finger
result
lower
level
enrich
data
shown
heavi
chain
alon
known
insolubl
davi
riechmann
thu
postul
fusion
zinc
finger
combin
proper
oxid
environ
could
make
heavi
chain
solubl
long
enough
pair
light
chain
lightheavi
chain
bind
result
solubl
fab
due
intracellular
product
target
protein
dna
display
broad
applic
varieti
proteinbas
interact
possibl
one
could
use
method
probe
acid
interact
vivo
unlik
phage
display
screen
well
protein
produc
vivo
could
access
chaperon
allow
proper
fold
furthermor
dna
display
simpler
phage
display
need
make
phage
prepar
entir
librari
screen
half
time
day
compar
three
day
signific
benefit
screen
immun
librari
eg
higher
affin
antibodi
due
vivo
matur
smaller
librari
divers
requir
antibodi
mous
origin
often
result
human
antimurin
antibodi
respons
schroff
et
al
reduc
undesir
immunogen
rel
common
exchang
mous
fr
correspond
region
human
antibodi
essenc
human
antibodi
clark
sever
strategi
human
develop
implement
approach
call
cdr
graft
nonhuman
cdr
graft
onto
given
human
sequenc
human
sequenc
select
either
similar
framework
sequenc
mous
framework
similar
cdr
mous
hwang
et
al
unfortun
approach
guarante
cdr
present
conform
wt
antibodi
consequ
signific
drop
affin
often
observ
hwang
et
al
necess
identifi
backmut
crucial
parent
framework
residu
human
antibodi
comput
model
difficult
often
empir
overcom
limit
novel
method
fast
effici
human
antibodi
develop
call
method
synthet
mous
cdr
fragment
ligat
pool
consensu
framework
sequenc
obtain
fulllength
variabl
heavi
light
chain
domain
framework
librari
sequenc
design
set
sequenc
use
ligat
cdr
region
antibodi
human
desir
similar
method
call
framework
shuffl
recent
describ
dall
aqua
et
al
method
framework
shuffl
use
sequenc
deriv
germlin
sequenc
cdr
link
pcr
signific
disadvantag
approach
antibodi
whole
new
set
pcr
primer
need
design
use
approach
isol
one
human
antibodi
equival
abil
compar
chimera
neutral
sarscov
infect
vero
cell
one
demonstr
improv
neutral
activ
hufr
method
combin
heavi
chain
differ
light
chain
gener
greater
divers
uniqu
antibodi
combin
potenti
increas
likelihood
find
benefici
human
scaffold
thu
method
provid
comprehens
approach
human
antibodi
without
loss
therapeut
function
potenti
improv
neutral
capabl
higher
affin
antibodi
attempt
increas
affin
top
antibodi
variant
use
gssm
methodolog
howev
methodolog
limit
affin
improv
use
evolv
mani
differ
properti
specif
protein
express
stabil
fold
etc
imposs
sampl
sequenc
space
within
given
protein
ie
amino
acid
protein
methodolog
allow
one
systemat
sampl
hot
spot
within
protein
combin
togeth
evalu
higher
resolut
area
interest
unlik
ration
approach
requir
knowledg
structur
protein
contrast
random
approach
errorpron
pcr
chemic
mutagenesi
sitedirect
mutagenesi
sequenc
overlap
extens
pcr
comprehens
thu
allow
access
substitut
miss
method
use
method
enzymat
protein
observ
thermost
haloalkan
dehalogenas
increas
combin
eight
singlepoint
mutat
discov
gray
et
al
eight
mutat
three
requir
multipl
base
pair
chang
codon
thu
chanc
find
mutat
use
errorpron
pcr
would
exceedingli
rare
kretz
et
al
similarli
optim
antibodi
present
three
five
amino
acid
posit
incorpor
reassembl
screen
requir
multipl
base
pair
chang
posit
tabl
ii
studi
best
singl
point
mutat
ie
result
improv
function
activ
antibodi
possibl
mutagenesi
entir
variabl
region
instead
simpli
cdr
done
improv
neutral
would
observ
best
human
antibodi
increas
affin
correl
improv
neutral
capac
howev
necessarili
contributor
also
possibl
chang
fine
specif
antibodi
bind
spike
protein
studi
neutral
cytomegaloviru
glycoprotein
bspecif
antibodi
shown
small
sequenc
chang
antibodi
demonstr
wide
varieti
neutral
capac
strictli
correl
affin
ohlin
et
al
lantto
et
al
barrio
et
al
differ
neutral
attribut
small
chang
fine
specif
observ
even
sequenc
chang
deriv
clonotyp
concentr
requir
antibodi
neutral
sar
infect
vero
cell
compar
well
antisar
antibodi
report
literatur
greenough
et
al
sui
et
al
coughlin
et
al
well
shown
inhibit
viral
replic
lung
age
mice
dose
mgkg
dose
similar
requir
palivizumab
antirsv
therapi
current
use
human
meissner
long
demonstr
potenti
antisar
antibodi
human
therapeut
given
likelihood
addit
emerg
pathogen
well
risk
bioterror
necessari
effect
tool
fight
biolog
threat
use
dna
display
method
discoveri
timelin
identif
novel
specif
antibodi
rapid
especi
immun
mice
requir
screen
requir
day
per
round
togeth
initi
construct
antibodi
librari
confirm
candid
hit
elisa
discoveri
new
antibodi
accomplish
within
approxim
three
week
optim
antibodi
necessari
technolog
requir
week
initi
construct
librari
confirm
hit
thu
caus
agent
new
pathogen
identifi
collect
technolog
provid
complet
solut
product
therapeut
antibodi
nation
institut
allergi
infecti
diseas
et
sarscov
antibodi
discoveryoptim
